Asset Details
Do you wish to reserve the book?
Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-KB inflammatory signaling pathway
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-KB inflammatory signaling pathway
Do you wish to request the book?
Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-KB inflammatory signaling pathway
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-KB inflammatory signaling pathway
2017
Overview
Xyloketal B （Xyl-B） is a novel marine compound isolated from mangrove fungus Xylaria sp. We previously demonstrated that pretreatment with XyI-B exerted neuroprotective effects and attenuated hypoxic-ischemic brain injury in neonatal mice. In the present study we investigated the neuroprotective effects of pre- and post-treatment with XyI-B in adult mice using a transient middle cerebral artery occlusion （tMCAO） model, and explored the underlying mechanisms. Adult male C57 mice were subjected to tMCAO surgery. For the pre-treatment, XyI-B was given via multiple injections （12.5, 25, and 50 mg.kgl-d1, ip） 48 h, 24 h and 30 min before ischemia. For the post-treatment, a single dose of XyI-B （50 mg/kg, ip） was injected at 0, 1 or 2 h after the onset of ischemia. The regional cerebral perfusion was monitored using a laser-Doppler flowmeter. TTC staining was performed to determine the brain infarction volume. We found that both pre-treatment with XyI-B （50 mg/kg） and post-treatment with XyI-B （50 mg/kg） significantly reduced the infarct volume, but had no significant hemodynamic effects. Treatment with Xyl-B also significantly alleviated the neurological deficits in tMCAO mice. Furthermore, treatment with XyI-B significantly attenuated ROS overproduction in brain tissues; increased the MnSOD protein levels, suppressed TLR4, NF-KB and iNOS protein levels; and downregulated the mRNA levels of proinflammatory cytokines, including IL-1β, TNF-α IL-6 and IFN-y. Moreover, XyI-B also protected blood-brain barrier integrity in tMCAO mice. In conclusion, XyI-B administered within 2 h after the onset of stroke effectively protects against focal cerebral ischemia; the underlying mechanism may be related to suppressing the ROS/TLR4/NF-KB inflammatory signaling pathway.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.